Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5

BACKGROUND: Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS from the MEASURE 5 study. METHODS: MEASURE 5 was a 52-week, Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Feng, Sun, Fei, Wan, Wei-Guo, Wu, Li-Jun, Dong, Ling-Li, Zhang, Xiao, Kim, Tae-Hwan, Sengupta, Raj, Šenolt, Ladislav, Wang, Yi, Qiu, Hao-Min, Porter, Brian, Haemmerle, Sibylle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722578/
https://www.ncbi.nlm.nih.gov/pubmed/32925287
http://dx.doi.org/10.1097/CM9.0000000000001099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722578/
https://www.ncbi.nlm.nih.gov/pubmed/32925287
http://dx.doi.org/10.1097/CM9.0000000000001099

Ejemplares similares